Stay updated on T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.

Latest updates to the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page
- CheckyesterdayChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; no substantive core-content changes were detected.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional drug information for Trastuzumab Deruxtecan, Capecitabine, and Paclitaxel. Notably, the total number of study locations has increased from 294 to 293, and several specific locations have been added or modified.SummaryDifference13%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check44 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.4%
Stay in the know with updates to T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the T-DXd vs Chemo in HER2-low HR+ MBC Clinical Trial page.